Overactive bladder syndrome management: physicians versus Artificial Intelligence

RUBILOTTA E1, Aloe M1, Mancini G1, Veccia A1, Bertolo R1, Mancini V2, Antonelli A1

Research Type

Clinical

Abstract Category

Female Lower Urinary Tract Symptoms (LUTS) / Voiding Dysfunction

Gold Pass video coming soon
Find out more

Abstract 14
Female LUTS
Scientific Podium Short Oral Session 2
Wednesday 7th October 2026
10:07 - 10:15
Parallel Hall 3
0.4 Brussels / 0.5 Paris
Capacity: 356
Bladder Outlet Obstruction Detrusor Overactivity Incontinence Pelvic Floor Overactive Bladder
1. Department of Urology, A.O.U.I. Verona, Verona, Italy., 2. Section of Urology and Renal Transplantation, University of Foggia, Policlinico di Foggia, Foggia, Italy.
Presenter
Links

Abstract

Hypothesis / aims of study
To compare medical and artificial intelligence (AI)-based agreement in the management of overactive bladder (OAB) syndrome.
Study design, materials and methods
In 2025, we prospectively compared how 3 expert urologists managed women referring OAB versus the suggestions of AI. OAB had to be the patient's main complaint. All medical evaluations were blind to AI advises. Other physicians reported to ChatGPT Web 3.0 Navigator all the patient’s data evaluated by clinicians and physical examination. Women included could be naïve for OAB, non-responder to first-line treatment, control in responder to therapy, complex cases.
Results
Data of 70 women (mean age 58.7 y.o.) were available: first outpatient visits were 87.1% (61), controls 12.9% (9). Overall, the agreement between physicians and AI was 72.9% (51). At first visits, concordance was found in 70.5% (43/61), disagreement in 18/61 (29.5%). Among controls, 8/9 (88.9%) showed same management. Women with medical indication to pharmacological therapy were 31/70 (44.3%) with agreement in management in 24/31 (77.4%), no concordance in 7/31 (22.6%). In this group, 25/31 (80.6%) were first visits, with disagreement of 24% (6/25) due to different drug class chosen; among the 6/31(19.4%) controls 1 (16.7%) had a different management. Among the 17/70 (24.3%) women with medical indication to OnabotulinToxinA (OBTA), 14/17 (82.4%) were naïve to this treatment and non-responders to previous first-line therapy; of these, 50% (7/14) achieved agreement between medical and IA. In all the 3 women who had a previous OBTA, with good response, there was a complete agreement to continue the same management. Complex cases and women with medical indications to conservative treatment were all first visits. Complex cases were 11/70 (15.7%) with a similar management in 72.7% (8). Conservative management were 15.7% with agreement in 9/11 (81.8%).
Interpretation of results
Among the first visits, conservative management achieved the highest concordance, while OBTA indication as second-line therapy the lowest (50%). This finding can be explained by the possibility of managing these patients in different ways. There was disagreement between physicians and AI In a relevant rate of women undergoing medical indication to pharmacological therapy. This was mainly due to a different type of drug chosen (antimuscarinic vs beta-3), not to a non-pharmacological strategy suggested by AI. A surprisingly higher than expected concordance rate was found in the management of complex cases, which could have numerous variables to consider.
Concluding message
There was fair agreement between medical and AI management for OAB, especially in controls. The lowest concordance was found in the choice of second-line therapy and in complex cases, which may have more variables and multiple managements. AI can help clinicians to quickly summarize the main available managements, but clinical experience still allows for appropriate and tailored indications for patients with OAB.
Disclosures
Funding No funding or grant Clinical Trial No Subjects Human Ethics not Req'd . Helsinki Yes Informed Consent Yes AI Not at all
Citation

Continence 19S (2026) 102491
DOI: 10.1016/j.cont.2026.102491

15/10/2026 08:31:56